MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the Obesity Society Conference. The study demonstrates how the Digbi Health program successfully alters the gut microbiome to produce compounds that increase the body's natural production of endogenous GLP-1 (glucagon-like peptide-1). This breakthrough approach shows promise in reducing GLP-1 medication dosages, improving weight loss, improving drug adherence, and lowering treatment costs for employers, health plans, and consumers while enhancing long-term weight loss outcomes.
As GLP-1 drugs such as Ozempic™, Wegovy™, and Zepbound™ become more widely prescribed for obesity, Digbi Health's research addresses common challenges associated with these medications, including gastrointestinal (GI) discomfort, drug adherence, and cost management.
Key Findings from the Study:
- Increased Endogenous GLP-1 Production: The study highlights how personalized dietary interventions that modulate the gut microbiome modulation naturally enhance the body's mechanism to produce GLP-1. This reduces the need for higher doses of GLP-1 medications, allowing patients to achieve similar weight loss and metabolic improvements with fewer side effects.
- Reduction in GI Discomfort: Over 40% of patients using GLP-1 medications experience GI discomfort, such as nausea and bloating. By increasing endogenous GLP-1 levels through the Digbi program, patients can reduce their dosage, leading to a reduction in these symptoms and improved comfort.
- Lower Dosage, Better Adherence: With enhanced natural GLP-1 production, patients can often reduce their reliance on external GLP-1 drugs, lowering their dosage while maintaining efficacy. This improvement results in better adherence to treatment and greater success in long-term weight management.
- Cost Reduction & Successful Tapering: By leveraging food and gut microbiome interventions, patients experience a reduced need for medication, which translates to lower healthcare costs. Additionally, the ability to taper off GLP-1 medications provides a more sustainable and cost-effective path to achieving their health goals.
“This study represents our commitment to quality innovation and positions Digbi Health at the forefront of the food-as-medicine and gut microbiome revolution. By naturally boosting GLP-1 levels, our approach offers a sustainable alternative or complement to pharmacotherapy, making weight loss treatment more accessible, less burdensome, and more effective,” said Ranjan Sinha, CEO of Digbi Health.
“The research we've done with Digbi Health shows great promise in understanding the role of the gut microbiome in predicting and managing obesity,” said Dr. Nova Szoka, MD, Associate Professor of Bariatric Surgery at West Virginia University. “This research could have significant implications for improving outcomes in patients struggling with weight management, particularly in enhancing the body's natural metabolic processes.”
Disclaimer:
Ozempic™, Wegovy™, and Zepbound™ are registered trademarks of their respective manufacturers. The use of these trade names in this press release is for informational purposes only and does not imply endorsement or affiliation with Digbi Health.
About Digbi Health:
Digbi Health pioneered Precision Biology, integrating gut microbiome, CGM, and genetics to holistically prevent and treat three of the top four most expensive healthcare conditions—Obesity, Cardiometabolic, and Digestive. Digbi's proven approach resonates with employers and health plans seeking new ways to eliminate fragmented point solutions and reduce healthcare costs, particularly GLP-1-related drug costs. The company’s competitive edge lies in its unique dataset and bioinformatics platform, which consolidates millions of data points across genetics, gut microbiome progression, metabolic health, and disease markers. This data empowers Digbi to personalize care, unearth patentable bio-signatures, generate impactful health risk profiles, and accurately stratify patient care for optimized treatment.
